SanegeneBio announced a global research and licensing collaboration with Eli Lilly (LLY) and Company. The companies will collaborate to advance RNAi candidates for metabolic diseases, based on SanegeneBio’s proprietary tissue selective delivery technology, LEAD.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Pfizer Clinches $10 Billion Metsera Deal as Novo Nordisk Loses Weight-Loss Drug Battle
- Insider Moves: JPMorgan, Adobe, Eli Lilly, McDonald’s, Merck
- Trump Weekly: China to suspend some controls on rare earths
- Eli Lilly price target raised to $1,090 from $1,069 at Morgan Stanley
- Trump Trade: Nvidia says no active talks on selling Blackwell chip to China